Determination of the biological variation of S100β and lactate dehydrogenase in disease-free patients with malignant melanoma

被引:5
|
作者
Trape, Jaume [1 ]
Montesinos, Jesus [2 ]
Franquesa, Josefina [1 ]
Sala, Maria [1 ]
Figols, Cristina [1 ]
Miguel, Ana [2 ]
Domenech, Montserrat [2 ]
机构
[1] Althaia Xarxa Assistencial Manresa, Serv Clin Chem, Dept Biol Diag, Manresa 08243, Catalonia, Spain
[2] Althaia Xarxa Assistencial Manresa, Serv Oncol, Manresa 08243, Catalonia, Spain
关键词
analytical goals; biological variation; LDH; reference change value; S100; SERUM CONSTITUENTS; LONG-TERM; CANCER;
D O I
10.1515/CCLM.2012.799
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Biological variation is important for determining analytical goals and for establishing the magnitude of change between two consecutive measurements. The aim of this study was to determine the biological variation for S100 beta and lactate dehydrogenase in patients diagnosed with malignant melanoma but without evidence of disease recurrence. Methods: The biological variation of S100 beta and lactate dehydrogenase was estimated from a mean of four consecutive measurements in 32 patients diagnosed with malignant melanoma but without evidence of disease recurrence, 3 months after tumor resection or 4 months after finishing adjuvant treatment. The mean sampling interval was 3 months. Results: Mean concentrations of S100 beta and lactate dehydrogenase were 0.0557 mu g/L and 6.3 mu kat/L, respectively. Between-run analytical variation was 3.5% at 0.181 mu g/L for S100 beta and 3.5% at 2.83 mu kat/L for lactate dehydrogenase. Biological variations obtained for S100 beta and lactate dehydrogenase were 14.2% and 8.2%, respectively. The analytical goals (defined as 50% of biological variation) were 7.1% for S100 beta and 4.1% for lactate dehydrogenase. Conclusions: The estimation of biological variation allows us to calculate analytical goals and reference change values. These are necessary tools for the correct interpretation of serial measurements in patient follow-up.
引用
收藏
页码:927 / 929
页数:3
相关论文
共 50 条
  • [41] Comparison of S100 protein and MIA protein as serum marker for malignant melanoma
    Djukanovic, D
    Hofmann, U
    Sucker, A
    Rittgen, W
    Schadendorf, D
    ANTICANCER RESEARCH, 2000, 20 (3B) : 2203 - 2207
  • [42] Erratum: Elevated serum levels of S100 and survival in metastatic malignant melanoma
    J Atzpodien
    J Buer
    British Journal of Cancer, 1998, 77 : 854 - 854
  • [44] Clinical utility of serum S100 in the therapy monitoring of patients with high risk malignant melanoma.
    Molina, R.
    Auge, J. M.
    Domingo, J.
    Puig, S.
    Filella, X.
    Malvehy, J.
    Castel, T.
    TUMOR BIOLOGY, 2006, 27
  • [45] Prognostic value of S100/CD31 and S100/podoplanin double immunostaining in mucosal malignant melanoma of the head and neck
    Wermker, Kai
    Brauckmann, Till
    Klein, Martin
    Hassfeld, Stefan
    Schulze, Hans-Joachim
    Hallermann, Christian
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (09): : 1368 - 1374
  • [46] Serum S100 level is predictive of recurrence-free survival in patients with intermediate risk melanoma
    Amin, P
    Bar, A
    Reynolds, S
    Shapiro, R
    Harris, M
    Roses, D
    Bystryn, J
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 467 - 467
  • [47] S100 PROTEIN AND HMB-45 NEGATIVE RHABDOID MALIGNANT-MELANOMA - A TOTALLY DEDIFFERENTIATED MALIGNANT-MELANOMA
    LASKIN, WB
    KNITTEL, DR
    FRAME, JN
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1995, 103 (06) : 772 - 773
  • [48] IMPORTANCE OF THE IMMUNOHISTOCHEMICAL DEMONSTRATION OF S100 PROTEIN IN MALIGNANT-MELANOMA AND PIGMENTED NEVI
    SCHNEIDER, I
    BATTYANI, Z
    BORGYOGYASZATI ES VENEROLOGIAI SZEMLE, 1986, 62 (03): : 103 - 107
  • [49] IMMUNOHISTOCHEMICAL DEMONSTRATION OF S100 PROTEIN IN HUMAN-MALIGNANT MELANOMA AND PIGMENTED NEVI
    NAKAJIMA, T
    WATANABE, S
    SATO, Y
    KAMEYA, T
    SHIMOSATO, Y
    GANN, 1981, 72 (02): : 335 - 336
  • [50] Expression and clinical significance of S100 family genes in patients with melanoma
    Xiong, Ting-feng
    Pan, Fu-qiang
    Li, Dong
    MELANOMA RESEARCH, 2019, 29 (01) : 23 - 29